Updated:
Solventum Corp
Solventum, led by CEO Bryan Hanson, spun out of 3M in 2024 with $8.2B in revenue to operate as an independent medtech and health-IT company.
Solventum Corp
Solventum commenced trading on the NYSE on April 1, 2024, following 3M's decision to carve out its Health Care Business Group into an independent public company. Bryan Hanson, formerly CEO of Zimmer Biomet, became chief executive, inheriting a portfolio built from decades of 3M-manufactured products including Tegaderm dressings, Futuro braces, and the 360 Encompass coding platform. The spin-off was structured as a tax-free distribution to 3M shareholders, who received one Solventum share for every four 3M shares held (per the firm's SEC filings, 2024). The company operates across four segments: Medical Surgical, Dental Solutions, Health Information Systems, and Purification & Filtration. Core positions include advanced wound care, infection prevention, oral aligners via Clarity Aligners, and population-health analytics. In its first quarter as an independent entity, Solventum reported $2.1 billion in net sales, with roughly 55% of revenue generated outside the United States — predominantly in Europe and Asia-Pacific. The firm's restructuring plan targets $300 million in annual cost reductions by 2027, partly through consolidating its manufacturing footprint and supply chain. Solventum employs approximately 22,000 people globally, with major operational hubs in Maplewood, Minnesota and San Antonio, Texas. The company's balance sheet launched with $8.3 billion in long-term debt as part of the separation mechanics, a leverage profile that constrains near-term large-scale M&A. Five-year growth priorities center on expanding digital health subscriptions and winning share in value-based care contracts. In 2024, the firm elevated its activist-proof governance by adopting a classified board structure phased out over three years. Structurally, Solventum represents the largest medtech spin-off in recent history — a bet that the sum of 3M's healthcare parts is worth more when managed outside a multi-industry conglomerate facing unrelated litigation liabilities. The firm carries a legacy of applied-materials science from its parent but must now prove it can independently accelerate product cycles, integrate acquired technologies, and hold margin in a consolidating provider market.
General information
Firm type
Asset Manager
Year founded
2024
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Maplewood
Corporate office
Maplewood, MN, United States
Principals
Bryan Hanson
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs Solventum and what is the board structure?
Bryan Hanson serves as CEO, having joined from Zimmer Biomet shortly before the 2024 spin-off. The board launched with eleven directors, including 3M veterans and externally recruited medtech operators, and adopted a multi-year declassification schedule meaning all directors will stand for annual election by 2027 (per the firm's proxy statements, 2024).
What does Solventum actually sell, and who buys it?
The portfolio splits into four units: Medical Surgical (wound care, sterilization, patient monitoring), Dental Solutions (restoratives, aligners, bonding agents), Health Information Systems (clinical documentation, revenue-cycle management software), and Purification & Filtration (biopharma and industrial filtration). Customers range from hospital systems and dental practices to government health agencies and pharmaceutical manufacturers.
How much debt did Solventum take on at separation?
Solventum issued approximately $8.3 billion in debt instruments concurrent with the spin-off, proceeds of which were transferred to 3M. This capital structure means the company's near-term free cash flow is weighted toward deleveraging, with management targeting a leverage ratio closer to 3.0x EBITDA within two to three years (per the firm's Q2 2024 earnings presentation).
Does Solventum participate in acquisitions or only organic growth?
The firm has stated M&A is a capital-allocation priority, particularly bolt-on acquisitions in digital health and dental technology. However, given the debt load at separation, near-term deals are likely to be smaller, tuck-in transactions funded from operating cash rather than large transformational acquisitions.
How is Solventum's R&D organized after leaving 3M?
Solventum retained centralized materials-science and application-engineering teams from its parent, but broke out a dedicated corporate R&D function independent of 3M's corporate labs. The company maintains a pipeline emphasis on bio-absorbable implants, AI-assisted radiology workflow, and connected wound-monitoring devices.
Where does most of Solventum's revenue come from geographically?
Roughly 45% of revenue originates in the United States, with the remainder spread across Europe, the Middle East, Africa, and Asia-Pacific. Germany, Japan, and China are its largest single-country markets outside the U.S. The firm operates manufacturing and distribution facilities in more than 30 countries (per the firm's annual regulatory disclosures, 2024).
What peer set do investors compare Solventum against?
Analyst coverage groups Solventum with diversified medtech peers such as Medtronic, Baxter, and Stryker — but its pure-play wound-care and health-IT combination means Zimmer Biomet, ConvaTec, and Cerner are also used as comparable-company proxies depending on the segment under review.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: